Tetanus and Botulism in the ICU — Comprehensive Management

Also known as Tetanus · Botulism · Lockjaw · Trismus · Opisthotonos · Tetanospasmin · Botulinum toxin · Descending flaccid paralysis · HTIG · Botulinum antitoxin

Tetanus and botulism — two clostridial neurotoxin diseases requiring ICU care. TETANUS: tetanus neurotoxin (TeNT) is transported retrogradely to the CNS and blocks GABA and glycine release from inhibitory interneurons → muscle spasms, rigidity, autonomic dysfunction. Management: wound debridement, antibiotics 7–10 days (metronidazole marginally favoured), antitoxin (human or equine IM — no outcome difference), benzodiazepines for spasms, magnesium sulfate targeting serum Mg 2–4 mmol/L, airway protection (about half of adults with generalised tetanus need ventilation), and full immunisation — natural infection does not confer immunity. BOTULISM: botulinum neurotoxin acts at peripheral cholinergic terminals → symmetrical cranial nerve palsies then descending flaccid paralysis with preserved consciousness. Management: botulinum antitoxin (BAT) immediately on clinical suspicion, intensive supportive care with ventilation when needed, recovery over weeks to months as new nerve terminals sprout. Infant botulism: BIG-IV (BabyBIG) shortens hospital stay.

medium22 referencesUpdated 1 Oct 202624 min readSource-verified · Oct 2026

Checked against its sources on 1 Oct 2026

Practise this topic

8 MCQs

The one-paragraph exam answer

Tetanus and botulism are clostridial neurotoxin diseases with mirror-image syndromes. Tetanus — Clostridium tetani neurotoxin (TeNT) is transported retrogradely to the CNS, where it cleaves synaptobrevin-2 in presynaptic glycine- and GABA-ergic inhibitory interneurons; the resulting disinhibition produces unopposed motor activity — spasms, rigidity, trismus, risus sardonicus — plus autonomic dysfunction, the feared complication that is now the prevailing cause of death where ventilation is available. Treat with wound debridement, antibiotics for 7–10 days (metronidazole marginally favoured over penicillin), antitoxin IM (human or equine — a 272-patient factorial trial found no difference), benzodiazepines, magnesium sulfate targeting serum Mg 2–4 mmol/L, airway protection (about half of adults with generalised tetanus need ventilation), and a full course of immunisation — natural infection does not confer immunity.^[14]^[1]^[6]^[4] Botulism — botulinum neurotoxin stays at peripheral cholinergic terminals, cleaves SNARE proteins and blocks acetylcholine release: symmetrical cranial nerve palsies then descending, symmetric flaccid paralysis, afebrile, alert, with intact sensation. Give botulinum antitoxin (BAT) immediately on clinical suspicion — early administration decreases mortality and ICU and hospital duration — then support with ventilation for weeks to months while new nerve terminals sprout.^[10]^[2]

Meet the patient

A previously well man arrives unable to open his mouth, days after a contaminated wound that has since healed — in up to 30% of tetanus cases no wound is found at all. His masseters are clenched, a fixed grimace furrows his face, and the slightest touch or sound fires a whole-body spasm. He is fully lucid — unlike many neurological infections, lucidity is preserved in tetanus. Trismus and dysphagia are almost always present at admission (93–98% and 83% in retrospective series); dyspnoea at admission is uncommon (5–10%) but signals impending airway compromise.^[14]

Across the unit, a person who injects drugs is descending the other way: ptosis, slurred speech, failing swallow — yet alert and oriented, with no sensory deficit. An abscess sits at a skin-popping site. California's wound botulism series documented exactly this epidemic among people who inject black tar heroin subcutaneously, with misdiagnosis and diagnostic delays of up to 64 days.^[10]^[12]

The organising question for both patients: is the toxin blocking inhibition (rigid — tetanus) or blocking excitation (flaccid — botulism)? Same toxin superfamily; the whole clinical difference lives in where the toxin acts.^[14]

References22Show

[1]Van Hao N, Loan HT, Yen LM, et al. Human versus equine intramuscular antitoxin, with or without human intrathecal antitoxin, for the treatment of adults with tetanus: a 2 × 2 factorial randomised controlled trial Lancet Glob Health, 2022.PMID 35561721
[2]Sobel J Botulism Clin Infect Dis, 2005.PMID 16163636
[3]Thwaites CL, Yen LM, Loan HT, et al. Magnesium sulphate for treatment of severe tetanus: a randomised controlled trial Lancet, 2006.PMID 17055945
[4]Attygalle D, Rodrigo N Magnesium as first line therapy in the management of tetanus: a prospective study of 40 patients Anaesthesia, 2002.PMID 12133096
[5]Rodrigo C, Samarakoon L, Fernando SD, et al. A meta-analysis of magnesium for tetanus Anaesthesia, 2012.PMID 23033859
[6]Ahmadsyah I, Salim A Treatment of tetanus: an open study to compare the efficacy of procaine penicillin and metronidazole Br Med J (Clin Res Ed), 1985.PMID 3928066
[7]Miranda-Filho Dde B, Ximenes RA, Barone AA, et al. Randomised controlled trial of tetanus treatment with antitetanus immunoglobulin by the intrathecal or intramuscular route BMJ, 2004.PMID 15003976
[8]Arnon SS, Schechter R, Maslanka SE, et al. Human botulism immune globulin for the treatment of infant botulism N Engl J Med, 2006.PMID 16452558
[9]Payne JR, Khouri JM, Jewell NP, et al. Efficacy of Human Botulism Immune Globulin for the Treatment of Infant Botulism: The First 12 Years Post Licensure J Pediatr, 2018.PMID 29229452
[10]Rao AK, Sobel J, Chatham-Stephens K, et al. Clinical Guidelines for Diagnosis and Treatment of Botulism, 2021 MMWR Recomm Rep, 2021.PMID 33956777
[11]O'Horo JC, Harper EP, El Rafei A, et al. Efficacy of Antitoxin Therapy in Treating Patients With Foodborne Botulism: A Systematic Review and Meta-analysis of Cases, 1923-2016 Clin Infect Dis, 2017.PMID 29293927
[12]Werner SB, Passaro D, McGee J, et al. Wound botulism in California, 1951-1998: recent epidemic in heroin injectors Clin Infect Dis, 2000.PMID 11049786
[13]Middaugh N, Edwards L, Chatham-Stephens K, et al. Wound Botulism Among Persons Who Inject Black Tar Heroin in New Mexico, 2016 Front Public Health, 2021.PMID 34976915
[14]Sudarshan R, Sayo AR, Renner DR, et al. Tetanus: recognition and management. Lancet Infect Dis, 2025.PMID 40543524
[15]Nepal G, Coghlan MA, Yadav JK, et al. Safety and efficacy of Magnesium Sulfate in the management of Tetanus: A systematic review. Trop Med Int Health, 2021.PMID 34403179
[16]Lebeda FJ, Cer RZ, Mudunuri U, et al. The zinc-dependent protease activity of the botulinum neurotoxins. Toxins (Basel), 2010.PMID 22069621
[17]Monash A, Tam J, Rosen O, et al. Botulinum Neurotoxins: History, Mechanism, and Applications. A Narrative Review. J Neurochem, 2025.PMID 40762356
[18]Dilena R, Pozzato M, Baselli L, et al. Infant Botulism: Checklist for Timely Clinical Diagnosis and New Possible Risk Factors Originated from a Case Report and Literature Review. Toxins (Basel), 2021.PMID 34941698
[19]Cox N, Hinkle R Infant botulism. Am Fam Physician, 2002.PMID 11996423
[20]Yen LM, Thwaites CL Tetanus. Lancet, 2019.PMID 30935736
[21]Ergönül Ö, Kolsuz S, Figueroa JP Tetanus. Lancet, 2026.PMID 41544646
[22]Arnon SS, Schechter R, Inglesby TV, et al. Botulinum toxin as a biological weapon: medical and public health management JAMA, 2001.PMID 11209178